Abstract
The amount of patients which develop chronic irreversible illness rises as the life expectancy grows among countries. When cancer patients step into final stages of their illness the complexity of questions and situations is evident. Frequently, terminally ill cancer patients choose to use unprescribed therapies at their own risk to alleviate suffering. When a generalist doctor comes across these situations, bioethical questions tend to raise among physician’s minds when assisting the patient and family. In this paper we argue about phosphoethanolamine supplement scenario: the different points of view of regulatory agencies; bioethical considerations; theoretical aspects of the molecule as phospholipid precursor; the biological importance the relation to others systems in different levels; pre-clinical and clinical safety data.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Family & Community Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
